Featured Article

Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death

Ignacio Melero, Izaskun Gabari, Iñigo Tirapu, Ainhoa Arina, Guillermo Mazzolini, Elena Baixeras, Esperanza Feijoo, Carlos Alfaro, Cheng Qian, and Jesús Prieto

Centro de Investigación Médica Aplicada (CIMA), Facultad de Medicina, Gene Therapy Unit, Universidad de Navarra, 31008 Pamplona, Spain

Abstract

Purpose: Systemic treatment with an anti-ICAM-2 monoclonal antibody (mAb; EOL4G8) eradicates certain established mouse tumors through a mechanism dependent on the potentiation of a CTL-mediated response. However, well-established tumors derived from the MC38 colon carcinoma cell line were largely refractory to this treatment as well as to intratumor injection of a recombinant adenovirus encoding interleukin-12 (IL-12; AdCMVIL-12). We sought to design combined therapy strategies with AdCMVIL-12 plus anti-ICAM-2 mAbs and to identify their mechanism of action.

Experimental Design: Analysis of antitumor and toxic effects were performed with C57BL/6 mice bearing established MC38 tumors. Anti-ovalbumin T-cell receptor transgenic mice and tumors transfected with this antigen were used for in vitro and in vivo studies on activation-induced cell death (AICD) of CD8+ T cells.

Results: Combined treatment with various systemic doses of EOL4G8 mAb plus intratumor injection of AdCMVIL-12 induced complete regression of MC38 tumors treated 7 days after implantation. Unfortunately, most of such mice succumbed to a systemic inflammatory syndrome that could be prevented if IFN-γ activity were neutralized once tumors had been rejected. Importantly, dose reduction of EOL4G8 mAb opened a therapeutic window (complete cure of 9 of 18 cases without toxicity). We also show that ICAM-2 ligation by EOL4G8 mAb on activated CTLs prevents AICD, thus extending IFN-γ production.

Conclusions: Combination of intratumor gene transfer of IL-12 and systemic anti-ICAM-2 mAb display synergistic therapeutic and toxic effects. CTL life extension resulting from AICD inhibition by anti-ICAM-2 mAbs is the plausible mechanism of action.

Introduction

ICAM-2 (CD102) is a glycosylated surface adhesion protein (1–3) expressed on endothelial cells and activated lymphocytes (2). Two ligands have been identified for this molecule: the leukocyte integrin LFA-1 (4) and the dendritic-cell-restricted C-type lectin DC-SIGN (CD209; Ref. 5).

In a recent study, we found that systemic administration of a mAb3 specific for ICAM-2 (EOL4G8) was able to induce complete regression of tumors derived from the CT26 colon carcinoma cell line (6). Such tumor regression is dependent on a functional immune system and correlates with the induction of tumor-specific cytotoxicity mediated by CD8+ T cells (6). The intrinsic mechanism underlying this antitumor activity is unknown, although it was found that EOL4G8 mAb was able to increase ICAM-2 binding to DC-SIGN (6). However, the relationship of this adhesion phenomenon to tumor immunity remains elusive. Recent evidence showed that cross-linking of human ICAM-2 was able to prevent the apoptosis of ICAM-2-transfected cells as well as in T cell lines (7). In those cellular systems, ICAM-2 binds ezrin in such a fashion that it becomes phosphorylated and recruits PI3K to the inner leaf of the plasma membrane, resulting in the elicitation of an antiapoptotic signaling cascade mediated by AKT (protein kinase B) phosphorylation and subsequent regulation of a number of substrates that result in the inhibition of BAD (7). Apoptosis is known to control clonal expansion in T cells to keep the immune response under control (8). AICD is a frequent outcome of T-lymphocyte activation through TCRs (8). Prominent roles played by FAS/FAS-L interactions (9), TNFR-II (10), IL-2 (11), IFN-γ (12) and the intracellular BCL-homologue BIM (13) have been described in this complex mechanism of immune regulation. Interference with AICD could be therapeutically useful to enhance desired immune responses.

IL-12 (14) is a potent antitumor agent (15) with a multi-layered mechanism of action that includes potentiation of CTL

The abbreviations used are: mAb, monoclonal antibody; PI3K, phosphatidylinositol 3’kinase; AICD, activation-induced cell death; TCR, T-cell receptor; TNFR, tumor necrosis factor receptor; IL, interleukin; NK, natural killer; FACS, fluorescence-activated cell sorting; pfu, plaque-forming unit(s); AdCMVIL-12, (suppress) adenovirus encoding IL-12.
responses, increases in NK activity (14), proinflammatory changes in tumor tissue (16, 17) and antiangiogenic effects (18). These actions of IL-12 are mainly mediated by its property of inducing IFN-γ release from T cells in an antigen-independent fashion (14). IFN-γ is also the main mediator of the severe systemic inflammatory shock that results from IL-12 overdose (19–22). Tumor gene transfer of IL-12 genes has been used to treat tumors with the idea of confining production of the cytokine to malignant tissue, thus limiting collateral damage inflicted by IFN-γ. Intratumor gene transfer of IL-12 with adenovirus is a safe and efficacious approach against rodent transplanted tumors (23–25). Many strategies have been explored to increase efficacy including combinations with other transgenes (25–28) and with agonistic anti-CD137 (4–1BB) mAbs (29, 30). Those anti-CD137 mAbs mediate antitumor effects (31) by enhancing a weak CTL response as a result of mAb interactions with CTLs (32), NK cells (33), and maturing dendritic cells (34).

In this study, we have found that (a) EOL4G8 anti-ICAM-2 mAb synergistically enhances the antitumor effects of intratumor gene transfer of IL-12, (b) this combination may result in lethal IFN-γ-related toxicity, and (c) ICAM-2 ligation by specific anti-ICAM-2 mAbs on activated CTLs can inhibit AICD both in vitro and in vivo, thus extending the viable period of IFN-γ production. These findings provide a rationale for the efficacy and toxicity of this treatment combination.

Materials and Methods

Cell Lines, mAbs, and Peptides. MC38 colon carcinoma cells (35) were cultured in DMEM+10% FCS (Life technologies SA., Barcelona, Spain), and CTL-2 immortalized T cells (American Type Culture Collection, Manassas, VA), which are absolutely dependent for growth on IL-2, were cultured in RPMI 1640 supplemented with 10 IU/ml human recombiant IL-2 (Chiron, Emeryville, CA) and 10% (v/v) FCS (Life Technologies, Inc.). EG.7 is a EL-4 lymphoma variant that has been transfected with an expression cassette to express full-length ovalbumin, which was obtained as a kind gift from Dr. M. Bevan (University of Washington, Seattle, WA; Ref. 36). EG.7 cells were cultured in DMEM+10%FCS.

EOL4G8 mAb (rat IgG2b) was obtained and purified by affinity chromatography on Sepharose-protein G columns (Amersham-Pharmacia Biotech, Uppsala, Sweden) as described previously (6). The anti-CD137 mAb (rat IgG2a) called 2A was kindly provided by Dr. Lieping Chen (Mayo Clinic, Rochester, MN; Ref. 37). Purified or fluorochrome-tagged anti-CD3, anti-CD4, anti-CD8, and anti-CD69, and 3C4 anti-ICAM-2 mAbs were from Pharmingen (San Diego, CA). Polyclonal rat IgG was purchased from Sigma (Alcobendas, Madrid, Spain). Peptide SIINFEKL (OVA 257–264) was synthesized manually in a multiple peptide synthesizer using FMOC [N-(9-fluorenylmethoxycarbonyl] chemistry. Ninhydrin test of Kaiser was used to monitor every step. At the end of the synthesis they were cleaved and deprotected with trifluoroacetic acid and washed with diethyl ether. Purity of the peptides was always above 90% as assessed by high-performance liquid chromatography.

Recombinant Adenoviruses. Recombinant adenoviruses carrying the p40 and p35 genes of murine IL-12 (AdCMVIL-12) or β-galactosidase (AdCMVlacZ) under the control of the cytomegalovirus (CMV) promoter have been described previously (38, 39). Adenoviruses were purified by double cesium chloride ultracentrifugation and extensively dialyzed against 10 mM Tris/1 mM MgCl2 before being stored at −80°C in the presence of 10% (v/v) glycerol. Titration was made by plaque assay (40).

Mice. Six-to-8-week-old C57BL/6 female mice were purchased from Harlan (Barcelona, Spain) and housed under specific-pathogen-free conditions in the University of Navarra. A breeding pair of OT-I transgenic mice in C57BL/6 background were obtained from Dr. Balbino Alarcón (Centro de Biología Molecular Severo Ochoa, Madrid, Spain) with permission from Dr. Francis R. Carbone (WEHI, Parkville, Victoria, Australia; 41) and were bred in our animal facility. All of the animal handling and in vivo experiments were performed following institutional guidelines and have been approved by the animal facility ethical committee.

In Vivo Tumor Experiments. Five × 105 MC38 cells were injected s.c. in the shaved right flank of syngeneic mice with a 280-G syringe (6). Tumor sizes were followed with a precision caliper and recorded at least weekly (most often every 3 days). The general well-being of the mice was recorded in comparison with control groups by observation, weighing, estimation of the amount of water drunk per cage, and watching the escaping response to stimulation by gentle poking with a blunt pencil.

To assess AICD in vivo, we injected 5 × 105 EG.7 cells in HBSS (100 μl/injection) s.c. in both flanks of OT-I transgenic mice and treated them i.p. with 100 μg of EOL4G8 or control antibody 4 days later. On day 7, draining lymph nodes were harvested from euthanized mice, and a cell suspension was obtained for flow cytometry studies.

FACS Staining and ELISA. Immunostaining with antibodies has been described previously (42). FITC-annexin V staining was performed with a commercial kit (PharMingen) in accordance with the manufacturer’s instructions. Samples were processed with a FACScalibur instrument (Becton-Dickinson, Madrid, Spain), and results were analyzed with CellQuest software.

Mytomycin-C was commercially purchased from Sigma and was used at 50 μg/ml during 2 h at 37°C to arrest the proliferation of MC38 cells that were washed three times in DMEM before setting 4-day cocultures with splenocytes.

IFN-γ ELISAs were from PharMingen and were performed according to the manufacturer’s instructions.

Results

Anti-ICAM-2 mAb + AdCMVIL-12 Combined Effects. Our published experiments (6) showed that i.p. treatment with two doses of 100 μg of EOL4G8 anti-ICAM-2 mAb could cure a fraction of tumors derived from s.c. inoculation of MC38 colon cancer cells in syngeneic mice, if given when tumor nodules were still unpalpable (as early as day 0 to day 4 after tumor cell inoculation). By contrast, if treatment onset was postponed to day 7 after tumor cell injection, no curative effects
were seen, and tumors progressed to kill the mouse, albeit with some delay if compared with control antibody-treated mice (6). In experiments shown in Table 1, we confirmed those treatment failures, because in a group of five mice that were treated with EOL4G8 mAb i.p on days 7, 9, and 11 after s.c. injection of MC38 cells, none of the tumors was rejected.

Table 1 Combined treatment with EOL4G8 mAb i.p. and intratumoral AdCMVIL-12 (IL-12-encoding adenovirus) synergize both for therapeutic effects and toxicity

Results from two experiments in which C57BL/6 mice received injections s.c. of $5 \times 10^5$ MC38 cells and were monitored for tumor growth or regression after receiving three doses of 150 $\mu$g of EOL4G8 or a control antibody that were given i.p. every other day starting on day 7 after tumor inoculation combined or not with intratumor injection of a single dose of $10^8$ pfu of AdCMVIL-12 on day 7.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Experiment 1</th>
<th>Experiment 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tumor complete regressions$^a$</td>
<td>Toxic deaths$^b$</td>
</tr>
<tr>
<td>4G8</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>Rat IgG</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>4G8 + Ad IL-12 i.t.</td>
<td>4/5</td>
<td>4/5</td>
</tr>
<tr>
<td>Rat IgG + Ad IL-12 i.t.</td>
<td>1/5</td>
<td>0/5</td>
</tr>
</tbody>
</table>

$^a$ Fraction of mice whose tumor nodules became undetectable.

$^b$ Fraction of mice that became severely ill between 2 and 3 weeks after treatment and that eventually died from tumor-unrelated causes.

$^c$ ND, not done; i.t., intratumoral/intratumorally.

After tumor inoculation for IFN-γ treatment, when mice were asymptomatic and most tumors were already macroscopically rejected or clearly shrinking in size. No toxic deaths took place in this group of seven mice (Fig. 1a), whereas three mice that did not receive anti-IFN-γ died on days 23, 25, and 30 from a toxic syndrome (data not shown). In the group that had been treated with EOL4G8+/AdCMVIL-12 and that received anti-IFN-γ treatment, tumors were eradicated in five of seven mice (Fig. 1b), whereas AdCMVIL-12 + control antibody gave rise to only one tumor cure in seven cases (Fig. 1c). Interestingly, in the animals that had been treated with AdCMVIL-12 and three doses of EOL4G8 mAb and that were rescued with neutralizing anti-IFN-γ mAb on day 21, the two progressing tumors resulted from regrowth of an already shrinking tumor and from the relapse of a tumor nodule that had remained undetectable for 2 weeks after anti-IFN-γ mAb administration. These results highlight the activities of IFN-γ in the toxic reaction and in the therapeutic activity. Concentrations of IFN-γ in sera of mice (n = 7) that have received $10^8$ pfu AdCMVIL-12 into MC38 tumors, plus a 100-μg dose of EOL4G8 i.p., were analyzed 6 days after treatment. Their IFN-γ concentrations were slightly higher than those of mice that had received AdCMVIL-12 and control antibody, although the difference did not reach statistical significance (Fig. 1b).

Dose Reduction of Anti-ICAM-2 Permits Significant Efficacy and Eliminates Toxicity. To find a therapeutic window for the combined treatment with AdCMVIL-12+EOL4G8 mAb, we treated a group of 18 mice bearing s.c. MC38 tumors implanted 7 days earlier. These mice received $10^5$ pfu of AdCMVIL-12 intratumorally and a single dose of 150 μg of EOL4G8 i.p. immediately after. Nine of those mice underwent complete tumor regression (Fig. 2a), whereas another mouse of the group experienced a transient disappearance of the tumor nodule. All of the mice in this group were carefully inspected every day, and no signs of serious illness were detected (they remained active and steady to stimulation, showing general well-being). As a control, one group received AdCMVIL-12 intratumorally without antibody and only 1 of 6 rejected its tumor (Fig. 2b; differences between the AdCMVIL-12 and the AdCMVIL-12+EOL4G8 groups were significant with $P < 0.01$ according to Fisher’s exact test). In another control group, mice received an intratumoral injection of the saline vehicle (Fig. 2c).
Parallel experiments demonstrated *in vivo* gene transduction of a minority of MC38 cells, mainly in the trajectory of the injecting needle (not shown). Such *in vivo* gene transduction of MC38 cells was checked with intratumoral injections of Ad-CMV-LacZ encoding for the reporter gene β-galactosidase followed by X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining of frozen sections.

**ICAM-2 Is Expressed on Activated CTLs.** We have previously shown that ICAM-2 expression dramatically increases in mouse T cells on activation with concanavalin A+IL-2 from almost undetectable levels (6). When splenocytes from OT-I TCR-transgenic mice, which express a transgenic TCR specific for the ovalbumin peptide SIINFEKL (OVA257–264) bound to the MHC class I molecule H2-Kb, were stimulated with the synthetic peptide at 10 ng/ml, high levels of ICAM-2 (CD102) expression were detected with the mAbs EOL4G8 and 3C4 (Fig. 3a) on CD8+ cells. Interestingly, freshly isolated lymphocytes from such mice were virtually negative for EOL4G8 mAb staining both in the CD4+ and CD8+ subpopulations (Fig. 3b), indicating that ICAM-2 expression on T cells can be controlled by antigen stimulation. ICAM-2 is also expressed on immortalized murine CTL lines like CTLL-2, which

---

**Fig. 1 a,** Late *in vivo* neutralization of IFN-γ during treatment with AdCMVIL-2 + EOL4G8 anti-ICAM-2 mAb avoids toxicity and permits therapeutic effects. Diameter follow-up of tumor nodules derived from the s.c. injection of MC38 cells on day 0 that were treated as indicated on day 7 with 10⁸ pfu of AdCMVIL-12 inside the tumor nodule. *Top graph,* mice received three i.p. doses of 150 μg of EOL4G8 mAb on days 7, 9, and 11, and one i.p. dose of ascites fluid containing a neutralizing anti-IFN-γ mAb on day 21; *middle graph,* mice received a similar course, but with control polyclonal rat antibody and saline; *bottom graph,* control group, received an intratumoral (i.t.) volume of 100 μl saline buffer on day 7. *Not shown,* another group of three mice received a course similar to that in the top panel but with an injection of polyclonal rat IgG (instead of anti-IFN-γ treatment) on day 21; all of the mice died from toxicity between days 24 and 30 after tumor inoculation. The fraction of tumor-free surviving mice is given in each panel. In b, IFN-γ serum concentrations (mean ± SE) of seven mice per group 6 days after receiving 10⁸ pfu of AdCMVIL-12 i.t. + 100 μg of EOL4G8 mAb or control antibody i.p.

**Fig. 2** Dose reduction of EOL4G8 mAb in combined treatment with AdCMVIL-12 permits antitumor therapy without lethal toxicity. Experiments are similar to those in Fig. 1, in which the indicated groups of mice received 10⁸ pfu of AdCMVIL-12 intratumorally (i.t.). *Top graph,* mice received an i.p. dose of 150 μg of EOL4G8 mAb immediately after the adenovirus; *middle panel,* mice did not receive antibody; *bottom panel,* another group of mice were implanted with the same MC38 tumor cells and were left without treatment. Fraction of tumor-free survival is given in each graph. No signs of toxicity were recorded during a 3-month close follow up of the animals that rejected their tumors.
also expressed activation antigens such as CD137 (4–1BB) and CD69 (Fig. 3c). In addition, ICAM-2 can be detected on CD8⁺ T-cell blasts from the spleen of mice cured from MC38 tumors restimulated for 4 days with mitomycin-C-treated MC38 cells plus 10 IU/ml of IL-2, thus indicating that activated CTLs with specificity for tumor antigens can interact with the anti-ICAM-2 therapeutic mAb (Fig. 3d).

**ICAM-2 Cross-Linking Inhibits AICD in CD8⁺ T Cells Both in Vitro and in Vivo.** Human ICAM-2 cross-linking has been reported to transmit apoptosis-inhibitory signals in a number of cellular systems (7). Apoptosis, a natural outcome of TCR stimulation, thought to play a major role in the regulation of the immune response (8). FAS or TNFR ligation on cell surface (9, 10), as well as activation of the proapoptotic molecule BIM, have been involved in this activity, which is counteracted by BCL-2 (13). Accordingly, stimulation of OT-1 splenocytes with 1 ng/ml OVA257–264 peptide + 5 IU/ml IL-2 for 6 days resulted in 60–70% apoptosis of CD8⁺ transgenic T cells, which were observed by FACS as cells that were stained both by annexin V coupled to FITC and by phycoerythrin-tagged anti-CD8α (Fig. 4, a and b). However, if EOL4G8 or 3C4 anti-ICAM-2 mAbs were applied to the cultured cells at 20 μg/ml, then the induction of apoptosis (measured as annexin V⁺-CD8⁺ cells) was partially inhibited with corresponding higher percentages of viable CD8⁺ cells that did not bind annexin-V (Fig. 4, a and b). This effect can also be clearly seen with the number of cellular events satisfying the electronic gating for living lymphocytes (Fig. 4b). However, no difference was seen in the rate of proliferation during the first 3 days of culture as measured with carboxyfluorescein succinimidyl ester-labeled lymphocytes or by [3H]-thymidine uptake into DNA (data not shown; confirming our previous data in Ref. 6). EOL4G8 mAb also failed to change the output of IFN-γ into the tissue culture medium of OVA257–264-stimulated OT-I splenocytes within the first 48 h after stimulation again confirming our previous data (data not shown and Ref. 6). By contrast, if IFN-γ concentrations released into the culture medium were assessed after 6 days of culture, there was a 4- to 5-fold increase of the concentration of IFN-γ in those cultures containing 10 μg/ml of EOL4G8 mAb (Fig. 4c), which can be interpreted as the result of the extension of the life span of stimulated CD8⁺ T cells.

To assess whether anti-ICAM-2 mAb were inhibiting
CD8$^+$ T-cell apoptosis in vivo, EG.7 tumor cells that express ovalbumin were injected s.c. into both flanks of OT-I mice. Four days later, mice were systemically treated with EOL4G8 or with polyclonal rat antibody as a control. As can be seen in Fig. 5, 3 days after antibody treatment, the draining lymph nodes of EOL4G8 mAb-treated mice contained less double-stained CD8$^+$ lymphocytes with annexin V-FITC as a marker of apoptotic cells. In a, percentage of CD8$^+$ viable and nonviable cells is provided. In b, both annexin V staining and percentage of cell events within the forward scatter (FSC) and side scatter (SSC) features of viable cells are provided (% calculated from a ratio of viable events: total events that is also provided in the indicated figure). c, IFN-$\gamma$ concentrations assessed by ELISA in the supernatant of cultures as those in a and b. Data are representative of four experiments similarly performed. R1, region 1; R2, region 2.

**Discussion**

This study shows the synergistic effects of systemic anti-ICAM-2 mAb and IL-$\gamma$12 gene transfer into tumor tissue. Such synergy was associated not only with a potent therapeutic activity but also with a potentially lethal systemic inflammatory shock. In addition, a plausible mechanistic explanation of the synergy is provided because cross-linking of ICAM-2 on the plasma membrane of activated CD8$^+$ T cells was able to prevent AICD, thereby intensifying the total output of IFN-$\gamma$ during the response.

Intratumor IL-$\gamma$12 gene transfer with recombinant adenovirus is efficacious in several rodent tumors (23–25) but could be toxic above certain doses because of the overproduction of IFN-$\gamma$ (22). Overdosing could also dampen the immune respon-
In vivo inhibition of activation-induced T-cell death by treatment with anti-ICAM-2 mAbs. Flow cytometry analysis of CD8\(^+\) lymphocytes stained with annexin-V obtained from the draining lymph nodes of TCR transgenic OT-I mice harvested 7 days after bilateral s.c. injection of EG.7 cells (OVA transfected EL-4). Groups of four mice each were treated on day 4 with 100 \(\mu\)g of either control polyclonal antibody (left) or EOL4G8 mAb (right). Each plot graph represents 10\(^4\) events from eight pooled inguinal lymph nodes and provides the percentage of double-stained CD8\(^+\) annexin-V\(^+\) cells. Results are representative of two experiments similarly performed.

![Graph showing Annexin-V and CD8 levels](image)

siveness of the host (43). Certain mouse strains, such as C57BL/6 are more prone to suffer a lethal syndrome when treated with AdCMVIL-12 (22). With 10\(^8\) pfu of AdCMVIL-12 given intratumorally, none of the treated C57BL/6 animals showed any signs of toxicity, but a very limited tumor efficacy was observed with this particular tumor model. It should be noted that a similar dose, if given i.v. instead of intratumorally to this strain, would be lethal in 6–10 days because of toxic shock mediated by IFN-\(\gamma\) (22).

The combination of 10\(^8\) pfu of AdCMVIL-12 intratumorally and three every-other-day doses of 150 \(\mu\)g of EOL4G8 mAb displayed a very dramatic and abrupt antitumor activity because most MC38-derived tumors were rapidly rejected, and the mice appeared otherwise healthy. The true synergistic nature of the therapeutic combination is shown because neither agent on its own would cause such an effect. However, during the 3rd week after treatment initiation, a high proportion of mice died from a condition with symptoms similar to those seen after overdosing AdCMVIL-12 i.v. (22), but with a much later onset. The involvement of IFN-\(\gamma\) in the toxicity was proved by showing that in vivo IFN-\(\gamma\) neutralization by specific mAbs 2 weeks after starting this treatment course, when most tumors were already rejected, prevented lethal toxicity. We observed that two tumors progressed on IFN-\(\gamma\) neutralization, one after being macroscopically undetectable and the other after being already shrinking its size. Both observations underscore the role of IFN-\(\gamma\) in the antitumor activity of IL-12, as has been confirmed in other immunotherapeutic regimes (15).

A clear therapeutic synergy could be observed also in the absence of lethal toxicity if only one dose (instead of three doses) of anti-ICAM-2 antibody were administered i.p. concomitantly with AdCMVIL-12 intratumor injection, thus allowing a dose-dependent therapeutic window. Anti-CD137 agonistic mAbs (37), which also have potent antitumor properties on their own (31, 37), have demonstrated synergistic effects with IL-12 intratumoral gene transfer against a colon cancer and in a metastatic breast cancer model, with no systemic toxicity reported, at least at the doses tested (29, 30).

The idea of combining immunopotentiating mAbs and IL-12 gene transfer to malignant cells will be important in the clinic. In support of this point, our results from a recently finished clinical trial, using escalating intratumoral doses of a first generation recombinant adenovirus encoding human IL-12 against advanced gastrointestinal tumors, have taught us that the effect of this gene therapy approach is not efficacious enough by itself.\(^4\) Therefore, combination strategies are needed, and, among those, those showing truly synergistic complementary mechanisms of action should be preferred (25). Anti-CD40 antibodies (44) also could be considered an alternative that is worth testing in combination with AdCMVIL-12, although, in this case, even the antibody as a single agent caused a lethal systemic inflammatory syndrome in mice (45). Thus, comparative studies of anti-ICAM-2, anti-CD137, and anti-CD40 in combination with IL-12 intratumor gene transfer have become one of our experimental priorities.

AdCMVIL-12 antitumor activity is attributed to CTL generation (39) and to increases in NK and NK T-cells activity (38), as well as to antiangiogenic actions (38). The mechanism or mechanisms of action of the EOL4G8 mAb are less well defined. Involvement of CTLs has been proved, but the intrinsic mechanism leading to their potentiation is not worked out (6). A recent publication showed that human ICAM-2, either as naturally expressed or as a transfected molecule in ICAM-2-negative cells, inhibited apoptosis on overexpression or cross-linking (7). The effect was studied in detail and was found to involve a chain of signaling events including ICAM-2-associated ezrin, PI3K, and AKT (PKB) and the inhibition of BAD (7). The prosurvival effect was very intense against apoptosis caused by growth factor deprivation and staurosporin treatment, as well as by FAS cross-linking.

In our hands, ICAM-2 cross-linking in vitro was capable of preventing induction of T-cell death by antigen in TCR-transgenic T cells stimulated with agonistic peptide and IL-2. Moreover, treatment with anti-ICAM-2 mAb in vivo prevented the induction of apoptosis of TCR-transgenic CD8\(^+\) lymphocytes located at lymph nodes that drain the area in which tumor cells expressing the relevant antigen had been injected. This antipoptotic effect extended the life span of some of the responding

\(^4\) B. Sangro et al., manuscript in preparation.
CD8+ T cells with the overall result of a higher output of IFN-γ into the culture supernatant. Such an antiapoptotic effect was clearly dissociated from proliferation or early cytokine secretion. Anti-CD137 mAbs have also been described to be primarily antiapoptotic on activated CTLs (46). Activation-induced T-cell death is conceived as an important homeostatic mechanism to regulate immune responses. A role in AICD has been described for ligation of the T-cell surface proteins FAS and TNFR p75 as well as for the cytokines IFN-γ and IL-2 (9–12). The molecule BIM seems to be the major intracellular player in the connection of the apoptotic pathway to the mitochondria (13). Our hypothesis is that ICAM-2, when cross-linked with the antibody, sets in motion a signaling pathway that interferes with these cascades. Anti-CD137 mAbs may exert a similar type of effect leading also to effective tumor immunity (46, 47).

Alternatively or complementarily, EOL4G8 mAb has been shown to enhance the avidity of the ICAM-2/DC-SIGN interaction (6). This would provide the therapeutic antibody with the opportunity to enhance the immune response by acting on the synapse formed by preactivated T cells and dendritic cells. In this regard, we have preliminary evidence showing that ICAM-2 is located in the T-cell/APC contact area in an early and antigen-independent fashion.5

In conclusion, we herein describe an efficacious combined strategy for cancer treatment encompassing IL-12 intratumoral gene transfer and systemic anti-ICAM-2 antibody treatment that requires caution because it can result in lethal toxicity. Both the efficacy and the late-onset toxicity are probably related to the ability of the anti-ICAM-2 mAbs to prevent the AICD of T lymphocytes, thus extending the effector time of IFN-γ-producing CTLs.

Acknowledgments

We acknowledge Helena Villanueva, Verónica Marín, and Juan Perea for expert technical assistance. We are grateful to Rubén Hernández-Alcoceba, Juanjo Lasarte, Gloria González-Aseguinolaza, and Pablo Sarobe for scientific discussion and critical readings.

References


Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death

Ignacio Melero, Izaskun Gabari, Iñigo Tirapu, et al.


Updated version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/9/10/3546

Cited articles This article cites 47 articles, 20 of which you can access for free at: http://clincancerres.aacrjournals.org/content/9/10/3546.full.html#ref-list-1

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/9/10/3546.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.